The voltage-gated calcium channel blocker lomerizine is neuroprotective in motor neurons expressing mutant SOD1, but not TDP-43

Journal of Neurochemistry

Volumn 130, Issue 3, 2014, Pages 455-466

  Tran, Luan T ^a   Gentil, Benoit J ^a   Sullivan, Kathleen E ^a   Durham, Heather D ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

amyotrophic lateral sclerosis; FUS; lomerizine; SOD1; TDP 43; voltage gated calcium channel

Indexed keywords

CALCIUM ION; COPPER ZINC SUPEROXIDE DISMUTASE; FUSED IN SARCOMA PROTEIN; GLUTAMIC ACID; LOMERIZINE; MUTANT PROTEIN; TAR DNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; ATTENUATION; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CELL INCLUSION; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; DISEASE MODEL; DRUG ACTIVITY; EMBRYO; EXCITOTOXICITY; IMPAIRED MITOCHONDRIAL TRAFFICKING; MITOCHONDRIAL FRAGMENTATION; MITOCHONDRION; MOTONEURON; MOUSE; NERVE CELL CULTURE; NERVE FIBER TRANSPORT; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; WILD TYPE;

AMYOTROPHIC LATERAL SCLEROSIS; FUS; LOMERIZINE; SOD1; TDP-43; VOLTAGE-GATED CALCIUM CHANNEL;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CELL SURVIVAL; CELLS, CULTURED; DNA-BINDING PROTEINS; GENE TRANSFER TECHNIQUES; HOMEOSTASIS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; MICE; MITOCHONDRIA; MOTOR NEURONS; MUTATION; NEUROPROTECTIVE AGENTS; PIPERAZINES; SPINAL CORD; SUPEROXIDE DISMUTASE;

EID: 84904565950     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12738     Document Type: Article

References (65)

1. Aggarwal S., and, Cudkowicz M., (2008) ALS drug development: reflections from the past and a way forward. Neurotherapeutics 5, 516-527.
2. 2+ currents and oxidative metabolism in dissociated mammalian CNS neurons. Brain Res. 619, 263-270.
3. Alexianu M. E., Ho B.-K., Mohamed A. H., La Bella V., Smith R. G., and, Appel S. H., (1994) The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann. Neurol. 36, 846-858.
4. Allen M. J., Lacroix J. J., Ramachandran S., Capone R., Whitlock J. L., Ghadge G. D., Arnsdorf M. F., Roos R. P., and, Lal R., (2012) Mutant SOD1 forms ion channel: implications for ALS pathophysiology. Neurobiol. Dis. 45, 831-838.
5. Arai T., Hasegawa M., Akiyama H., et al,. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602-611.
6. Armstrong G. A., and, Drapeau P., (2013) Calcium channel agonists protect against neuromuscular dysfunction in a genetic model of TDP-43 mutation in ALS. J. Neurosci. 33, 1741-1752.
7. Awata N., Sakai T., Satomi O., and, Kawashima T., (1995) Metabolism of lomerizine hydrochloride in rats. Yakugaku Zasshi 115, 120-129.
8. Batulan Z., Taylor D. M., Aarons R. J., Minotti S., Doroudchi M. M., Nalbantoglu J., and, Durham H. D., (2006) Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis. Neurobiol. Dis. 24, 213-225.
9. Beers D. R., Ho B. K., Siklos L., et al,. (2001) Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis. J. Neurochem. 79, 499-509.
10. Bensimon G., Lacomblez L., and, Meininger V., and ALS-Riluzole Study Group (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 330, 585-591.
11. 2+ rises and consequent oxygen radical production. J. Neurosci. 18, 7722-7738.
12. Cheung E. C., McBride H. M., and, Slack R. S., (2007) Mitochondrial dynamics in the regulation of neuronal cell death. Apoptosis 12, 979-992.
13. 2+ determine motoneuron vulnerability in rat spinal cord in vivo. Neuropharmacology 52, 1219-1228.
14. De Vos K. J., Chapman A. L., Tennant M. E., et al,. (2007) Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet. 16, 2720-2728.
15. Droppelmann C. A., Wang J., Campos-Melo D., Keller B., Volkening K., Hegele R. A., and, Strong M. J., (2013) Detection of a novel frameshift mutation and regions with homozygosis within ARHGEF28 gene in familial amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. Frontotemporal. Degener. 15, 444-451.
16. Durham H. D., Roy J., Dong L., and, Figlewicz D. A., (1997) Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J. Neuropathol. Exp. Neurol. 56, 523-530.
17. Elliott J. L., and, Snider W. D., (1995) Parvalbumin is a marker of ALS-resistant motor neurons. NeuroReport 6, 449-452.
18. Ghadge G. D., Slusher B. S., Bodner A., et al,. (2003) Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc. Natl Acad. Sci. USA 100, 9554-9559.
19. Guzman J. N., Sanchez-Padilla J., Wokosin D., Kondapalli J., Ilijic E., Schumacker P. T., and, Surmeier D. J., (2010) Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468, 696-700.
20. Ilijic E., Guzman J. N., and, Surmeier D. J., (2011) The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol. Dis. 43, 364-371.
21. Imai N., Konishi T., Serizawa M., and, Okabe T., (2007) Do the effects of long-term lomerizine administration differ with age? Intern. Med. 46, 683-684.
22. Ince P., Stout N., Shaw P., Slade J., Hunziker W., Heizmann C. W., and, Baimbridge K. G., (1993) Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol. Appl. Neurobiol. 19, 291-299.
23. Ishii M., Iizuka R., Kiuchi Y., Mori Y., and, Shimizu S., (2011) Neuroprotection by lomerizine, a prophylactic drug for migraine, against hydrogen peroxide-induced hippocampal neurotoxicity. Mol. Cell. Biochem. 358, 1-11.
24. Israelson A., Arbel N., Da C. S., Ilieva H., Yamanaka K., Shoshan-Barmatz V., and, Cleveland D. W., (2010) Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron 67, 575-587.
25. Jaiswal M. K., Zech W. D., Goos M., Leutbecher C., Ferri A., Zippelius A., Carri M. T., Nau R., and, Keller B. U., (2009) Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease. BMC Neurosci. 10, 64.
26. Junttila T., Koistinaho J., Reichardt L., Hidaka H., Okazaki K., and, Pelto-Huikko M., (1995) Localization of neurocalcin-like immunoreactivity in rat cranial motoneurons and spinal cord interneurons. Neurosci. Lett. 183, 100-103.
27. Kabashi E., Lin L., Tradewell M. L., et al,. (2010) Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum. Mol. Genet. 19, 671-683.
28. Kawahara Y., Kwak S., Sun H., Ito K., Hashida H., Aizawa H., Jeong S. Y., and, Kanazawa I., (2003) Human spinal motoneurons express low relative abundance of GluR2 mRNA: an implication for excitotoxicity in ALS. J. Neurochem. 85, 680-689.
29. Kriz J., Gowing G., and, Julien J. P., (2003) Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol. 53, 429-436.
30. Kruman I. I., Pedersen W. A., Springer J. E., and, Mattson M. P., (1999) ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp. Neurol. 160, 28-39.
31. Kuo J. J., Schonewille M., Siddique T., Schults A. N., Fu R., Bar P. R., Anelli R., Heckman C. J., and, Kroese A. B., (2003) Hyperexcitability of cultured spinal motoneurons from presymptomatic ALS mice. J. Neurophysiol. 91, 571-575.
32. Kuo J. J., Siddique T., Fu R., and, Heckman C. J., (2005) Increased persistent Na+ current and its effect on excitability in motoneurones cultured from mutant SOD1 mice. J. Physiol. 563, 843-854.
33. Kwiatkowski T. J., Jr, Bosco D. A., Leclerc A. L., et al,. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205-1208.
34. Lips M. B., and, Keller B. U., (1998) Endogenous calcium buffering in motoneurones of the nucleus hypoglossus from mouse. J. Physiol. 511 (Pt 1), 105-117.
35. Liu X., and, Hajnoczky G., (2009) Ca2 + -dependent regulation of mitochondrial dynamics by the Miro-Milton complex. Int. J. Biochem. Cell Biol. 41, 1972-1976.
36. Magrane J., Hervias I., Henning M. S., Damiano M., Kawamata H., and, Manfredi G., (2009) Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities. Hum. Mol. Genet. 18, 4552-4564.
37. Magrane J., Sahawneh M. A., Przedborski S., Estevez A. G., and, Manfredi G., (2012) Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J. Neurosci. 32, 229-242.
38. Miller R. G., Shepherd R., Dao H., Khramstov A., Mendoza M., Graves J., and, Smith S., (1996a) Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromusc. Disord. 6, 101-104.
39. Miller R. G., Smith S. A., Murphy J. R., Brinkmann J. R., Graves J., Mendoza M., Sands M. L., and, Ringel S. P., (1996b) A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 19, 511-515.
40. Neumann M., Sampathu D. M., Kwong L. K., et al,. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133.
41. Pieri M., Gaetti C., Spalloni A., Cavalcanti S., Mercuri N., Bernardi G., Longone P., and, Zona C., (2003) alpha-amino-3-hydroxy-5-methyl-isoxazole-4- propionate receptors in spinal cord motor neurons are altered in transgenic mice overexpressing human Cu, Zn superoxide dismutase (Gly(93)->Ala) mutation. Neuroscience 122, 47-58.
42. Reiner A., Medina L., Figueredo-Cardenas G., and, Anfinson S., (1995) Brainstem motoneuron pools that are selectively resistant in amyotrophic lateral sclerosis are preferentially enriched in parvalbumin: evidence from monkey brainstem for a calcium-mediated mechanism in sporadic ALS. Exp. Neurol. 131, 239-250.
43. Rosen D. R., Siddique T., Patterson D., et al,. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.
44. Rothstein J. D., Van Kammen M., Levey A. I., Martin L. J., and, Kuncl R. W., (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 38, 73-84.
45. Roy J., Minotti S., Dong L., Figlewicz D. A., and, Durham H. D., (1998) Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms. J. Neurosci. 18, 9673-9684.
46. 2+ concentrations using a dual-excitation ratiometric indicator based on green fluorescent protein. Sci. STKE 2002, P14.
47. Siklos L., Engelhardt J., Harati Y., Smith R. G., Joo F., and, Appel S. H., (1996) Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann. Neurol. 39, 203-216.
48. Siklõs L., Engelhardt J. I., Alexianu M. E., Gurney M. E., Siddique T., and, Appel S. H., (1998) Intracellular calcium parallels motoneuron degeneration in SOD-1 mutant mice. J. Neuropathol. Exp. Neurol. 57, 571-587.
49. Simuni T., Borushko E., Avram M. J., Miskevics S., Martel A., Zadikoff C., Videnovic A., Weaver F. M., Williams K., and, Surmeier D. J., (2010) Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov. Disord. 25, 2863-2866.
50. Song W., Song Y., Kincaid B., Bossy B., and, Bossy-Wetzel E., (2012) Mutant SOD1(G93A) triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1alpha. Neurobiol. Dis. 51, 72-81.
51. Takuma H., Kwak S., Yoshizawa T., and, Kanazawa I., (1999) Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann. Neurol. 46, 806-815.
52. Tateno M., Sadakata H., Tanaka M., et al,. (2004) Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum. Mol. Genet. 13, 2183-2196.
53. Tortarolo M., Grignaschi G., Calvaresi N., et al,. (2006) Glutamate AMPA receptors change in motor neurons of SOD1G93A transgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral sclerosis-like disease. J. Neurosci. Res. 83, 134-146.
54. Tradewell M. L., and, Durham H. D., (2010) Calpastatin reduces toxicity of SOD1G93A in a culture model of amyotrophic lateral sclerosis. NeuroReport 21, 976-979.
55. Tradewell M. L., Cooper L., Minotti S., and, Durham H. D., (2011) Calcium dysregulation, mitochondrial pathology and protein aggregation in a culture model of amyotrophic lateral sclerosis: mechanistic relationship and differential sensitivity to intervention. Neurobiol. Dis. 42, 265-275.
56. Tradewell M. L., Yu Z., Tibshirani M., Boulanger M.-C., Durham H. D., and, Richard S., (2012) Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. Hum. Mol. Genet. 21, 136-149.
57. Traynor B. J., Bruijn L., Conwit R., Beal F., O'Neill G., Fagan S. C., and, Cudkowicz M. E., (2006) Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67, 20-27.
58. Van Damme P., Leyssen M., Callewaert G., Robberecht W., and, Van Den B. L., (2003) The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. 343, 81-84.
59. Van Damme P., Braeken D., Callewaert G., Robberecht W., and, Van Den B. L., (2005) GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 64, 605-612.
60. Vance C., Rogelj B., Hortobagyi T., et al,. (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211.
61. Vande Velde C., Miller T. M., Cashman N. R., and, Cleveland D. W., (2008) Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc. Natl. Acad. Sci. USA 105, 4022-4027.
62. Vande Velde C., McDonald K. K., Boukhedimi Y., McAlonis-Downes M., Lobsiger C. S., Bel H. S., Zandona A., Julien J. P., Shah S. B., and, Cleveland D. W., (2011) Misfolded SOD1 associated with motor neuron mitochondria alters mitochondrial shape and distribution prior to clinical onset. PLoS ONE 6, e22031.
63. Vandenberghe W., Robberecht W., and, Brorson J. R., (2000) AMPA receptor calcium permeability, GluR2 expression, and selective motoneuron vulnerability. J. Neurosci. 20, 123-132.
64. Williams T. L., Day N. C., Ince P. G., Kamboj R. K., and, Shaw P. J., (1997) Calcium-permeable α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann. Neurol. 42, 200-207.
65. Zinman L., and, Cudkowicz M., (2011) Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol. 10, 481-490.